Dermatology Times

JUNE 2, 2024

James Song, MD, explains combination treatment efficacy, addresses comorbidities, and provides pearls to improve patient safety.

Dermatitis 52

Dermatitis Therapy Safety Treatments 52

The Dermatology Digest

FEBRUARY 18, 2025

Just days after snagging dual approvals for moderate-to-severe atopic dermatitis (AD) and prurigo nodularis (PN) in the European Union, nemolizumab (Nemluvio, Galderma) was also granted Marketing Authorization in the United Kingdom (UK) and Switzerland for AD and PN.

Dermatitis 36

Dermatitis Marketing Hospital Clinic 36

The Dermatology Digest

JANUARY 13, 2025

Nektar Therapeutics has completed target enrollment in its REZOLVE-AD Phase2bstudy of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis (AD). Proof-of-concept efficacy and safety data from a Phase1bstudy of rezpegaldesleukin in atopic dermatitis patients were presented at the 2023 EADV Congress.

Dermatitis 36

Dermatitis Clinic Eczema Therapy 36

The Dermatology Digest

DECEMBER 13, 2024

Food and Drug Administration (FDA) has approved nemolizumab (Nemluvio, Galderma) for the treatment of patients aged 12 and older with moderate to severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies.

Dermatitis 69

Dermatitis Safety Eczema Dermatology 69

Dermatology Times

MARCH 28, 2025

Lisa Swanson, MD, FAAD, discusses how pediatric atopic dermatitis (AD) treatment challenges include limited approved options, safety concerns, and adherence issues. Effective management requires balancing new therapies like Janus kinase (JAK) inhibitors with safety while supporting caregivers through education.

Dermatitis 36

Dermatitis Safety Education Therapy 36

The Dermatology Digest

FEBRUARY 10, 2025

Rezpegaldesleukin is an investigational biologic therapy that targets the interleukin-2 receptor complex to stimulate proliferation of inhibitory immune cells known as regulatory T cells. “We are pleased that rezpegaldesleukin has been designated a Fast Track product,” says Jonathan Zalevsky, Ph.D.,

Dermatitis 36

Dermatitis Therapy Office Safety 36

Dermatology Times

MARCH 14, 2025

Panelists discuss how varying degrees of JAK selectivity in targeted therapies affect treatment outcomes, safety profiles, and therapeutic decision-making in atopic dermatitis management.

Dermatitis 36

Dermatitis Treatments Safety Therapy 36

Dermatology Times

MARCH 3, 2025

Panelists discuss the systemic treatment option tralokinumab for pediatric atopic dermatitis (AD), focusing on its mechanism of action, efficacy, safety, and role in improving outcomes for children with moderate to severe disease.

Dermatitis 36

Dermatitis Therapy Safety Treatments 36

The Dermatology Digest

FEBRUARY 14, 2024

Food and Drug Administration (FDA) has accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis (PN) and for adolescents and adults with moderate to severe atopic dermatitis (AD). Galderma is planning for multiple regulatory submissions in 2024.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

Dermatology Times

FEBRUARY 24, 2025

The panelist discusses how a 28-year-old woman with moderate atopic dermatitis requires personalized, comprehensive management addressing hand involvement, corticosteroid concerns, and potential Janus kinase (JAK) inhibitor therapy, focusing on symptom relief, safety, and patient-specific factors.

Dermatitis 36

Dermatitis Safety Therapy Management 36

Dermatology Times

FEBRUARY 17, 2025

The panelist discusses how an 8-year-old girl with moderate to severe atopic dermatitis requires a comprehensive treatment approach focusing on dupilumab as a potential systemic therapy.

Dermatitis 36

Dermatitis Treatments Safety Therapy 36

The Dermatology Digest

FEBRUARY 8, 2024

This will be a game-changer if it pans out and may get us closer to disease cures via optimization of existing biological therapies,” he says. It has great efficacy and safety and is oral… [This means] no shot and no risk of anaphylaxis.” Hands Up for New CHE therapies Chronic hand eczema (CHE) will also get some love in 2024.

Dermatology 78

Dermatology Eczema Pharmaceutical Dermatitis 78

The Dermatology Digest

DECEMBER 13, 2024

Galderma) for the treatment of both atopic dermatitis and prurigo nodularis in the European Union (EU). IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation and skin barrier dysfunction in both atopic dermatitis and prurigo nodularis. Food and Drug Administration (FDA) in August 2024.

Dermatitis 36

Dermatitis Safety Marketing Therapy 36

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Eczema 36

Eczema Dermatitis Safety Therapy 36

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Eczema 36

Eczema Dermatitis Safety Therapy 36

The Dermatology Digest

JUNE 14, 2024

Food and Drug Administration (FDA) has cleared InnoCare Pharma’s investigational new drug application (IND) for ICP-332, a tyrosine kinase 2 (TYK2) inhibitor that’s being studied in moderate to severe atopic dermatitis (AD). Currently, no TYK2 inhibitors have obtained marketing approval for the treatment of AD.

Dermatitis 36

Dermatitis Marketing Safety Innovations 36

The Dermatology Digest

FEBRUARY 16, 2024

for the treatment of chronic spontaneous urticaria (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy. The safety profile of dupilumab in CSU was generally consistent with the known safety of Dupixent in its approved dermatological indications. and Novartis Pharmaceuticals).

Pharmaceutical 36

Pharmaceutical Safety Dermatitis Therapy 36

The Dermatology Digest

JULY 10, 2024

for use in moderate to severe atopic dermatitis (AD) in the NHS England. The interleukin-13 blocker is indicated for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate to severe AD, who are candidates for systemic therapy.

Dermatitis 36

Dermatitis Safety Dermatology Marketing 36

The Dermatology Digest

OCTOBER 26, 2024

Atopic dermatitis (AD) patients who switched to upadacitinib (Rinvoq, AbbVie) from dupilumab (Dupixent, Regeneron, and Sanofi) hit higher treatment targets, according to results from Period 2 of the LEVEL UP study. The most frequently reported TEAEs included nasopharyngitis, acne, upper respiratory tract infection, and atopic dermatitis.

Dermatitis 36

Dermatitis Treatments Pharmaceutical Eczema 36

The Dermatology Digest

MAY 6, 2024

The Phase 2a trial ( NCT05984784 ) evaluates the safety, pharmacokinetics, and efficacy of IMG-007 in adult patients with moderate-to-severe AD who had inadequate response to and/or intolerant of topical therapies. Key study endpoints include safety and percent change from baseline in eczema area and severity index (EASI) over time.

Safety 36

Safety Therapy Dermatitis Eczema 36

The Dermatology Digest

DECEMBER 18, 2023

New practice parameters from the Joint Task Force for Practice Parameter) recommend the use of topical corticosteroids or topical calcineurin inhibitors in patients with uncontrolled atopic dermatitis (AD) despite moisturizer use. Suggest the usage of crisaborole 2% ointment for mild to moderate atopic dermatitis. in a news release. “It

Dermatitis 36

Dermatitis Partnerships Therapy Diet 36

The Dermatology Digest

DECEMBER 19, 2023

Aldeyra Therapeutics’ investigational RASP modulator ADX-629 performed well in a Phase 2 clinical trial of patients with atopic dermatitis (AD), according to topline results. The primary endpoint of the clinical trial was safety and tolerability. No patients experienced flare requiring rescue therapy.

Dermatitis 36

Dermatitis Eczema Clinic Therapy 36

The Dermatology Digest

MARCH 11, 2024

In addition, results from the phase III ARCADIA clinical trials in atopic dermatitis (AD) found that nemolizumab-treated patients who responded at 16 weeks maintained skin and itch responses through to week 48, even when dosing was reduced from every four to every eight weeks. No new safety signals were observed in this trial.

Dermatitis 36

Dermatitis Safety Eczema Dermatology 36

The Dermatology Digest

OCTOBER 24, 2024

APG777 continues to show promise in atopic dermatitis (AD), according to early data. APG777, in single doses up to 1,200mg or multiple doses of 300mg, showed a well-tolerated safety profile. Apogee Therapeutics, Inc. The company expects to report 16-week topline data from Part A of the trial in the second half of 2025.

Sustainability 36

Sustainability Dermatitis Safety Clinic 36

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Eczema 28

Eczema Dermatitis Safety Therapy 28

The Dermatology Digest

MARCH 5, 2024

Pharmacokinetic (PK) data showed a half-life of approximately 75 days across doses tested and pharmacodynamic (PD) data showed, deep and sustained inhibition of key atopic dermatitis (AD) biomarkers pSTAT6 and TARC for ~3 months (longest follow-up available, with inhibition still ongoing at time of the data cut).

Injections 36

Injections Safety Sustainability Clinic 36

The Dermatology Digest

AUGUST 13, 2024

Nemolizumab was granted Breakthrough Therapy Designation in December 2019 and Priority Review in February 2024 by the U.S. The phase III OLYMPIA 1 and OLYMPIA 2 clinical trials evaluated the efficacy and safety of nemolizumab administered subcutaneously every four weeks in more than 500 patients with prurigo nodularis.

Dermatitis 36

Dermatitis Clinic Safety Dermatology 36

The Dermatology Digest

OCTOBER 10, 2024

KT-621 is an investigational first-in-class once daily, oral STAT6 degrader with dupilumab-like activity in preclinical models and the potential to address multiple allergic and atopic diseases including atopic dermatitis, asthma, and chronic obstructive pulmonary disease, among others.

Clinic 36

Clinic Injections Dermatitis Safety 36

First Derm

DECEMBER 26, 2023

Dandruff (Seborrheic Dermatitis) Dandruff, medically known as seborrheic dermatitis , is a common scalp condition marked by excessive shedding of skin cells. Skin Conditions (Eczema, Psoriasis, Contact Dermatitis) as Causes of Dry, Itchy Scalp Various skin conditions can lead to a dry, itchy scalp: a.

Management 49

Management Dermatitis Eczema Consultation 49

Aesthetics Advisor

MARCH 10, 2024

Randomized, double-blind, controlled trials suggest that excluding certain foods, such as eggs and chicken, can significantly improve atopic dermatitis. Eczema, also known as atopic dermatitis, is a chronic inflammatory skin disease. Previously, I talked about the safety and efficacy of other, more natural treatments.

Eczema 36

Eczema Diet Dermatitis Document 36

The Dermatology Digest

JANUARY 9, 2024

The engineered bacterium has been validated in skin cell lines and its delivery has been validated in mice. “We have developed a topical therapy with a targeted approach, using what nature already has. acnes to address atopic dermatitis. We engineered a bacterium that lives in the skin and made it produce what our skin needs.

Sebum 36

Sebum Dermatitis Safety Technology 36

The Dermatology Digest

JANUARY 8, 2024

This study was a 16-week, Phase 2, randomized, double-blind, parallel group, placebo controlled, dose-ranging, multicenter study that evaluated the safety and efficacy of lutikizumab in 153 adult patients with moderate to severe HS who had previously failed anti-TNF therapy. Serious adverse events (SAEs) occurred in 5.3%

Medical 36

Medical Clinic Therapy Eczema 36

US Dermatologt Partners

SEPTEMBER 23, 2024

Chronic skin conditions – poorly managed chronic skin conditions like eczema and dermatitis may damage or dilate blood vessels around the eyes. A dermatologist can provide treatments like: Laser therapy – lasers may be used around the eye area for a multitude of purposes. These treatments can be very effective but are not without risk.

Treatments 41

Treatments Chemical Peels Skincare Routine Sun Protection 41

Aesthetics Advisor

JUNE 16, 2024

As with so many skin-care trends that have come before, this one is rooted in medicine — in this case, regenerative medicine, which is centered on developing and applying therapies to help the body heal itself. But the authors also noted that “further studies are needed to assess the long-term efficacy and safety of this technique.”

Injections 36

Injections Aromatherapy Ingredients Moisturization 36

US Dermatologt Partners

JANUARY 24, 2024

Multiple sclerosis (MS) –People with MS, especially those who receive disease-modifying therapies, are significantly more likely to develop psoriasis, according to research presented at the 2021 Consortium of Multiple Sclerosis Centers. Symptoms include abdominal cramping, changes in bowel movements, and blood in the stool.

Management 36

Management Skin Health Medical Dermatology 36

The Dermatology Digest

AUGUST 4, 2023

1 Explanations for the decline included poor compliance, poor reimbursement, fear of skin cancer, and the promise of newer therapies, said Dr. Richard. After at least 12 weeks of concomitant combination therapy, their facial vitiligo scores improved, and their total body vitiligo scores improved. It’s a great adjunct therapy.

Eczema 36

Eczema Private Practice Therapy Dermatitis 36

The Dermatology Digest

DECEMBER 5, 2024

Some of the key highlights related to atopic dermatitis (AD) therapies include: APG777 APG777 is a novel, subcutaneous, extended half-life monoclonal antibody (mAb) targeting interleukin (IL)-13. Apogee Therapeutics recently hosted its first R&D Day, which featured updates across its entire portfolio.

Portfolios 74

Portfolios Dermatitis Sustainability Injections 74